Landry Robert E 4

What Happened

• Robert E. Landry, a director of CYTOKINETICS, reported acquisition-type awards on 2026-05-27 totaling 7,152 shares: 2,851 shares reported as a direct award and 4,301 shares reported as a derivative award. Both items were reported with an acquisition price of $0.00 (no cash paid) and therefore show $0 in purchase consideration on the Form 4.

Key Details

• Transaction date: 2026-05-27 (filing date 2026-05-27).
• Grants reported: 2,851 shares (award) and 4,301 shares (derivative award), total 7,152 shares; price reported $0.00 for each line.
• Shares owned after transaction: Not specified in the provided summary of the filing (see the Form 4 for full holdings).
• Footnotes/notable items: The 4,301-share item is reported as a derivative security (commonly represents RSUs, restricted stock units, or similar), but the filing does not specify the exact instrument or any tax-withholding details.
• Timeliness: Transaction and filing share the same date in the submission provided—no late filing is indicated here.

Context

• A $0.00 price on a Form 4 typically indicates an award or vesting event (compensation/board grant) rather than a market purchase. Derivative awards often convert into common shares under vesting terms; the filing does not state whether these shares are vested or subject to future conditions.
• Awards to directors are common and reflect compensation practices; they are not the same as open-market purchases by insiders and should be interpreted accordingly. For full details on vesting, restrictions, and post-transaction holdings, consult the complete Form 4 filing (accession 0001061983-26-000056).